FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087703986> ?p ?o ?g. }

• W2087703986 endingPage "1064.e1" @default.
• W2087703986 startingPage "1058" @default.
• W2087703986 abstract "Purpose Examine the prevalence of myopia and high myopia, at 6 and 9 months postterm and 2 and 3 years postnatal in preterm children with birth weights < 1251 g who developed high-risk prethreshold retinopathy of prematurity (ROP) in the neonatal period and participated in the Early Treatment for ROP Study. Design Randomized controlled clinical trial. Participants Four hundred one infants who developed prethreshold ROP and were determined to have a significant risk (≥15%) of poor structural outcomes without treatment. Children underwent cycloplegic retinoscopy at examinations between 6 months postterm and 3 years' postnatal age. Intervention Eyes were randomized to receive treatment at high-risk prethreshold ROP (early treated [ET]) or conventional management (CM), with treatment only if threshold ROP developed. Main Outcome Measures Myopia (spherical equivalent ≥ 0.25 diopters [D]) or high myopia (≥5.00 D) at each visit. Results Prevalences of myopia were similar in treated eyes in the ET and CM groups, increasing from approximately 58% to 68% between 6 and 9 months, with little change thereafter. Both ET and CM eyes showed an increasing prevalence of high myopia, approximately 19% at 6 months and increasing 4% to 8% at successive examinations. Zone of ROP and presence or absence of plus disease had little effect on prevalence of myopia or high myopia between ages 6 months and 3 years. However, eyes with ROP residua (straightened temporal vessels or macular heterotopia) showed a higher prevalence of myopia and high myopia than eyes without residua. Conclusions Approximately 70% of high-risk prethreshold ROP eyes were myopic in early childhood, and the proportion with high myopia increased steadily between ages 6 months and 3 years. Timing of treatment of high-risk prethreshold ROP did not influence refractive error development. There was little difference in prevalence of myopia or high myopia between eyes with zone I and eyes with zone II ROP, nor between eyes with plus disease and eyes with no plus disease. However, prevalence of myopia and high myopia was higher in eyes with retinal residua of ROP than in eyes with normal-appearing posterior poles, highlighting the importance of follow-up eye examinations of infants who had prethreshold ROP. Examine the prevalence of myopia and high myopia, at 6 and 9 months postterm and 2 and 3 years postnatal in preterm children with birth weights < 1251 g who developed high-risk prethreshold retinopathy of prematurity (ROP) in the neonatal period and participated in the Early Treatment for ROP Study. Randomized controlled clinical trial. Four hundred one infants who developed prethreshold ROP and were determined to have a significant risk (≥15%) of poor structural outcomes without treatment. Children underwent cycloplegic retinoscopy at examinations between 6 months postterm and 3 years' postnatal age. Eyes were randomized to receive treatment at high-risk prethreshold ROP (early treated [ET]) or conventional management (CM), with treatment only if threshold ROP developed. Myopia (spherical equivalent ≥ 0.25 diopters [D]) or high myopia (≥5.00 D) at each visit. Prevalences of myopia were similar in treated eyes in the ET and CM groups, increasing from approximately 58% to 68% between 6 and 9 months, with little change thereafter. Both ET and CM eyes showed an increasing prevalence of high myopia, approximately 19% at 6 months and increasing 4% to 8% at successive examinations. Zone of ROP and presence or absence of plus disease had little effect on prevalence of myopia or high myopia between ages 6 months and 3 years. However, eyes with ROP residua (straightened temporal vessels or macular heterotopia) showed a higher prevalence of myopia and high myopia than eyes without residua. Approximately 70% of high-risk prethreshold ROP eyes were myopic in early childhood, and the proportion with high myopia increased steadily between ages 6 months and 3 years. Timing of treatment of high-risk prethreshold ROP did not influence refractive error development. There was little difference in prevalence of myopia or high myopia between eyes with zone I and eyes with zone II ROP, nor between eyes with plus disease and eyes with no plus disease. However, prevalence of myopia and high myopia was higher in eyes with retinal residua of ROP than in eyes with normal-appearing posterior poles, highlighting the importance of follow-up eye examinations of infants who had prethreshold ROP." @default.
• W2087703986 created "2016-06-24" @default.
• W2087703986 creator A5004706203 @default.
• W2087703986 creator A5034055218 @default.
• W2087703986 creator A5058634391 @default.
• W2087703986 creator A5060667246 @default.
• W2087703986 creator A5062460881 @default.
• W2087703986 creator A5073469490 @default.
• W2087703986 creator A5075748423 @default.
• W2087703986 date "2008-06-01" @default.
• W2087703986 modified "2023-09-30" @default.
• W2087703986 title "Progression of Myopia and High Myopia in the Early Treatment for Retinopathy of Prematurity Study" @default.
• W2087703986 cites W1507203673 @default.
• W2087703986 cites W1914990260 @default.
• W2087703986 cites W1970399717 @default.
• W2087703986 cites W1983444807 @default.
• W2087703986 cites W1985714809 @default.
• W2087703986 cites W1993539081 @default.
• W2087703986 cites W2007932556 @default.
• W2087703986 cites W2011591151 @default.
• W2087703986 cites W2012796665 @default.
• W2087703986 cites W2018301427 @default.
• W2087703986 cites W2031435430 @default.
• W2087703986 cites W2038352994 @default.
• W2087703986 cites W2042055033 @default.
• W2087703986 cites W2054334806 @default.
• W2087703986 cites W2057336076 @default.
• W2087703986 cites W2063052157 @default.
• W2087703986 cites W2084824872 @default.
• W2087703986 cites W2099196941 @default.
• W2087703986 cites W2102378892 @default.
• W2087703986 cites W2104113341 @default.
• W2087703986 cites W2113634797 @default.
• W2087703986 cites W2121413118 @default.
• W2087703986 cites W2125892915 @default.
• W2087703986 cites W2156238444 @default.
• W2087703986 cites W2167112651 @default.
• W2087703986 cites W2168664240 @default.
• W2087703986 cites W2396339900 @default.
• W2087703986 cites W2917970078 @default.
• W2087703986 cites W4206470368 @default.
• W2087703986 cites W4248231685 @default.
• W2087703986 doi "https://doi.org/10.1016/j.ophtha.2007.07.028" @default.
• W2087703986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18423871" @default.
• W2087703986 hasPublicationYear "2008" @default.
• W2087703986 type Work @default.
• W2087703986 sameAs 2087703986 @default.
• W2087703986 citedByCount "92" @default.
• W2087703986 countsByYear W20877039862012 @default.
• W2087703986 countsByYear W20877039862013 @default.
• W2087703986 countsByYear W20877039862014 @default.
• W2087703986 countsByYear W20877039862015 @default.
• W2087703986 countsByYear W20877039862016 @default.
• W2087703986 countsByYear W20877039862017 @default.
• W2087703986 countsByYear W20877039862018 @default.
• W2087703986 countsByYear W20877039862019 @default.
• W2087703986 countsByYear W20877039862020 @default.
• W2087703986 countsByYear W20877039862021 @default.
• W2087703986 countsByYear W20877039862022 @default.
• W2087703986 countsByYear W20877039862023 @default.
• W2087703986 crossrefType "journal-article" @default.
• W2087703986 hasAuthorship W2087703986A5004706203 @default.
• W2087703986 hasAuthorship W2087703986A5034055218 @default.
• W2087703986 hasAuthorship W2087703986A5058634391 @default.
• W2087703986 hasAuthorship W2087703986A5060667246 @default.
• W2087703986 hasAuthorship W2087703986A5062460881 @default.
• W2087703986 hasAuthorship W2087703986A5073469490 @default.
• W2087703986 hasAuthorship W2087703986A5075748423 @default.
• W2087703986 hasConcept C118487528 @default.
• W2087703986 hasConcept C141071460 @default.
• W2087703986 hasConcept C168563851 @default.
• W2087703986 hasConcept C187212893 @default.
• W2087703986 hasConcept C259533 @default.
• W2087703986 hasConcept C2776148792 @default.
• W2087703986 hasConcept C2778257484 @default.
• W2087703986 hasConcept C2778376644 @default.
• W2087703986 hasConcept C2779234561 @default.
• W2087703986 hasConcept C2779501256 @default.
• W2087703986 hasConcept C2779918416 @default.
• W2087703986 hasConcept C2781135284 @default.
• W2087703986 hasConcept C54355233 @default.
• W2087703986 hasConcept C71924100 @default.
• W2087703986 hasConcept C86803240 @default.
• W2087703986 hasConceptScore W2087703986C118487528 @default.
• W2087703986 hasConceptScore W2087703986C141071460 @default.
• W2087703986 hasConceptScore W2087703986C168563851 @default.
• W2087703986 hasConceptScore W2087703986C187212893 @default.
• W2087703986 hasConceptScore W2087703986C259533 @default.
• W2087703986 hasConceptScore W2087703986C2776148792 @default.
• W2087703986 hasConceptScore W2087703986C2778257484 @default.
• W2087703986 hasConceptScore W2087703986C2778376644 @default.
• W2087703986 hasConceptScore W2087703986C2779234561 @default.
• W2087703986 hasConceptScore W2087703986C2779501256 @default.
• W2087703986 hasConceptScore W2087703986C2779918416 @default.
• W2087703986 hasConceptScore W2087703986C2781135284 @default.
• W2087703986 hasConceptScore W2087703986C54355233 @default.
• W2087703986 hasConceptScore W2087703986C71924100 @default.
• W2087703986 hasConceptScore W2087703986C86803240 @default.

• next